PFE Q4 CY2025 Deep Dive: Obesity Pipeline and Cost Discipline Face Post-COVID Headwinds

Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% year on year to $17.56 billion. The company expects the full year’s revenue to be around $61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.66 per share was 16.2% above analysts’ consensus estimates.

Is now the time to buy PFE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Pfizer closed the fourth quarter with revenue ahead of Wall Street expectations, but the market reacted negatively due to a combination of year-over-year sales decline and shrinking operating margins. Management explained that the drop in COVID-19 product demand weighed heavily on overall results, while non-COVID products delivered solid operational growth. CEO Albert Bourla cited the impact of a “narrow recommendation for vaccines in the US” as a driver behind lower COVID product sales and highlighted double-digit operational growth in recently launched and acquired products. Additionally, Pfizer’s ongoing cost optimization initiatives and a focus on pipeline development were emphasized as responses to the changing business environment.

Looking forward, Pfizer’s guidance reflects a transitional period driven by patent expirations and the need to offset declining COVID-19 revenues. Management stressed the importance of its obesity and oncology pipelines, particularly the next-generation GLP-1 therapies, to drive growth after anticipated generic competition. CFO Dave Denton acknowledged the near-term challenges, noting that, “our COVID products are expected to trend lower again in 2026,” and outlined continued investment in research and development—especially in obesity and digital capabilities—as key to delivering longer-term growth beyond 2028.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to lower COVID-19 product sales, solid contributions from core products, and accelerating investment in next-generation therapies, while also addressing cost controls and product pipeline prioritization.

• COVID-19 product decline: Lower vaccine and antiviral demand sharply reduced operational revenue, as management pointed to a “narrow recommendation” for vaccines in the US and fewer COVID-19 cases overall.
• Growth in core products: Medicines such as Abrisvo, Eliquis, Prevnar, and the Vyndaqel family posted notable operational gains, with non-COVID products growing 9% operationally year-over-year.
• Obesity pipeline momentum: The quarterly highlight was progress in Pfizer’s obesity portfolio, especially the GLP-1 receptor agonist PF-3944, which showed promising weight loss and tolerability data, supporting monthly dosing and upcoming phase 3 studies.
• R&D portfolio realignment: The company deprioritized or divested certain pipeline assets, resulting in non-cash impairments but allowing reinvestment into high-potential areas like oncology and obesity, with more than 20 pivotal studies planned for the coming year.
• Cost optimization initiatives: Approximately $600 million in manufacturing savings were achieved in 2025, with future cost reductions expected through further digitization and artificial intelligence (AI) integration, particularly in R&D and manufacturing.

Drivers of Future Performance

Pfizer’s outlook for the next year is shaped by investment in new therapies, cost-saving measures, and the transition away from COVID-19 product reliance.

• Obesity and metabolic pipeline investments: Management is counting on its GLP-1 receptor agonist and combination therapies, such as PF-3944 and the ultra-long-acting amylin analog, to create differentiated chronic weight management solutions, with multiple phase 3 trials and potential first approvals starting in 2028.
• Patent expirations and generic entry: The upcoming loss of exclusivity (LOE) for key products, notably Vyndaqel in 2028, is expected to compress revenue, prompting increased focus on newer launches and pipeline assets to offset these declines.
• AI-driven productivity gains: The company is embedding artificial intelligence across R&D, manufacturing, and commercial operations to drive efficiency, accelerate clinical development, and improve go-to-market productivity, supporting cost management and freeing resources for reinvestment.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be watching (1) the progression and readouts from key phase 3 studies in Pfizer’s obesity and oncology portfolios, (2) the impact of generic competition and the company’s ability to stabilize non-COVID revenue streams, and (3) the implementation of AI initiatives to drive operational efficiencies and cost reductions. Additional attention will be given to upcoming product launches and regulatory milestones, particularly in chronic weight management and rare disease.

Pfizer currently trades at $25.73, down from $26.66 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.